DANBIO is a Danish nationwide database of patients with inflammatory arthritides who have been followed over time during different treatments.
DANBIO is mandatory to use for all rheumatologists treating rheumatoid arthritis in Denmark. DANBIO's secretariat is located at COPECARE.
Based on DANBIO research, we now know that, although the clinical responses vary between different treatments with Tumor-Necrosis-Factor-alpha (TNFα) inhibitors (i.e. a group of biologic drugs) (Hetland et al., 2010), they all reduce radiographic progression (Ørnbjerg et al., 2013) in patients treated in daily clinical practice.
The effectiveness of newer biologics has also been studied (Leffers et al., 2011).
Furthermore, treatment with TNFα inhibitors does not seem to be associated with an increased risk of cancer (Dreyer et al., 2013).
Psoriatic arthritis and axial spondyloarthritis
Other results from DANBIO have shown, that the efficacy of the second and third treatment with a TNFα inhibitor is almost as good as the first treatment in patients who change from one TNFα inhibitor to another due to lack of efficacy (Glintborg et al., 2013).